Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Movapo (apomorphine hydrochloride)
pCPA File Number:
21010
Negotiation Status:
Concluded with an LOI
Indication(s):
Parkinson's Disease
Sponsor/Manufacturer:
Paladin Labs Inc.
CADTH Project Number:
SR0527-000
pCPA Engagement Letter Issued:
2018-06-29
Negotiation Process Concluded:
2019-03-27